健民集团(600976) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥747,334,981.28, a decrease of 14.27% compared to the same period last year[4] - The total profit for the quarter was ¥66,529,235.86, down 23.73% year-on-year[4] - The net profit attributable to shareholders was ¥65,111,696.75, reflecting a decline of 20.84% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥60,222,741.34, a decrease of 21.29% year-on-year[4] - The basic earnings per share for the quarter was ¥0.42, down 22.22% from the same period last year[5] - The weighted average return on equity decreased by 0.95 percentage points to 2.55%[5] - The company's net profit for the current period is CNY 288,603,789.34, a decrease of 11.09% compared to CNY 324,587,553.14 in the previous period[21] - Operating profit for the current period is CNY 304,365,030.94, down from CNY 352,785,660.72, reflecting a decline of 13.71%[21] - Total revenue from sales of goods and services for the current period is CNY 2,680,603,615.88, compared to CNY 3,120,748,668.08 in the previous period, indicating a decrease of 14.06%[24] - The basic and diluted earnings per share for the current period are both CNY 1.88, down from CNY 2.10 in the previous period[21] - The total comprehensive income attributable to the parent company's owners is CNY 285,737,321.93, a decrease from CNY 321,615,639.73 in the previous period[21] Assets and Liabilities - The company's total assets increased by 1.40% to ¥4,337,514,441.31 compared to the end of the previous year[5] - Current assets as of September 30, 2025, totaled CNY 2,587,186,889.28, slightly down from CNY 2,601,436,202.31 at the end of 2024[16] - Non-current assets increased to CNY 1,750,327,552.03 as of September 30, 2025, compared to CNY 1,676,193,203.82 at the end of 2024[17] - Total assets reached CNY 4,337,514,441.31, up from CNY 4,277,629,406.13 at the end of 2024[18] - Total liabilities decreased to CNY 1,737,330,864.95 from CNY 1,827,290,163.33 in the previous year[18] - Shareholders' equity increased to CNY 2,600,183,576.36 as of September 30, 2025, compared to CNY 2,450,339,242.80 at the end of 2024[18] - Cash and cash equivalents stood at CNY 175,220,075.80, up from CNY 163,173,887.90 at the end of 2024[16] - Accounts receivable rose to CNY 865,583,203.16 from CNY 807,667,332.99 in the previous year[16] - Inventory decreased to CNY 309,658,226.06 from CNY 354,311,612.84 at the end of 2024[16] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥139,050,345.38, an increase of 31.45%[10] - The net cash flow from operating activities is CNY 139,050,345.38, an increase from CNY 105,781,248.03 in the previous period[24] - The company reported a net cash outflow from financing activities of CNY -171,646,633.27, worsening from CNY -97,605,918.79 in the previous period[25] - The cash and cash equivalents at the end of the period stand at CNY 150,831,297.54, down from CNY 180,774,348.01 in the previous period[25] Segment Performance - The pharmaceutical manufacturing segment saw a revenue increase of 19.67% year-to-date, while the pharmaceutical commerce segment experienced a decline of 36.91%[8] - The net profit attributable to shareholders for the year-to-date period was ¥285,737,321.93, down 11.16% year-on-year, primarily due to reduced investment income from joint ventures and non-recurring gains and losses[8] Research and Development - Research and development expenses increased to CNY 78,318,937.23, up 29.66% from CNY 60,448,309.19 in the previous period[21]